News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FibroGen, Inc. Announces Presentation of Updated Results at European Respiratory Society Annual Congress



9/5/2012 10:03:41 AM

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., on Monday, September 3rd, presented the most recent results from its Phase 2 trial of FG-3019 as an oral presentation at the European Respiratory Society Annual Congress in Vienna, Austria. The title of the presentation in a late-breaker session of the meeting was “Phase 2 Trial of FG-3019, Anti-CTGF Monoclonal Antibody in Idiopathic Pulmonary Fibrosis: Preliminary Safety and Efficacy Results.”

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES